<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2019.91014</article-id><article-id pub-id-type="publisher-id">ACM-28595</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20190100000_40444670.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  儿童与成人系统性红斑狼疮的临床特点分析
  Clinical Characteristics of Systemic Lupus Erythematosus in Children and Adults
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>荆</surname><given-names>欣欣</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>大海</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>郭</surname><given-names>兴青</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>林</surname><given-names>毅</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>秋业</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>青岛大学附属医院儿科，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>07</day><month>01</month><year>2019</year></pub-date><volume>09</volume><issue>01</issue><fpage>80</fpage><lpage>87</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：探讨儿童与成人系统性红斑狼疮(systemic lupus erythematosus, SLE)临床表现及实验室指标的差异。方法：收集2013年4月~2017年6月在青岛大学附属医院首诊为系统性红斑狼疮患者，根据起病年龄分为儿童组(≤14岁)和成人组(&gt;15岁)，分别进行组间临床表现、实验室指标、受累系统数量、SLEDAI (systemic lupus erythematosus disease activity index, SLEDAI)评分的比较。结果：共纳入108例SLE患者，成人组67例，儿童组41例。儿童组与成人组相比，颜面皮疹(68.3%/37.3%)、肌炎(14.6%/3.0%)、消化系统受累(36.6%/9.0%)、精神神经系统症状(29.2%/9.0%)、合并感染(65.9%/44.8%)的发生率差异有统计学差异(P &lt; 0.05)。儿童组受累器官更多(t = 2.27)，SLEDAI评分更高(t = 2.03)，成人组与儿童组相比，呼吸系统受累率(56.7%/14.1%)差异有统计学意义(P &lt; 0.05)。结论：成人与儿童SLE存在相似之处，但儿童SLE受累系统更多，临床表现更重。
    Objective: To explore the difference of clinical manifestations and laboratory data between children and adults with systemic lupus erythematosus (SLE). Methods: Collected the clinical information of patients with systemic lupus erythematosus who were first diagnosed in the Affiliated Hospital of Qingdao University from April 2013 to June 2017. The patients were divided into children group (≤14 years old) and adults group (&gt;15 years old) according to the onset age. The clinical manifestations, laboratory data, number of affected systems and SLEDAI (systemic lupus ery-thematosus disease activity index) scores were compared between groups. Results: A total of 108 SLE patients were enrolled, including 67 adults and 41 children. Compared with the adults group, there was a statistically significant difference in facial rash (68.3%/37.3%), myositis (14.6%/3.0%), involved digestive system (36.6%/9.0%), neuropsychiatric symptoms (29.2%/9.0%) and the in-cidence of infection (65.9%/44.8%) (P &lt; 0.05). The children group had more organs involved (t = 2.27), and the SLEDAI score was higher (t = 2.03), indicating that the child’s condition was more serious. Conclusion: There are similarities between adults and children with SLE, but children with SLE have more involved systems and more clinical manifestations. 
  
 
</p></abstract><kwd-group><kwd>系统性红斑狼疮，儿童，成人，临床特点, Systemic Lupus Erythematosus</kwd><kwd> Children</kwd><kwd> Adults</kwd><kwd> Clinical Characteristics</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>儿童与成人系统性红斑狼疮的临床特点分析<sup> </sup></title><p>荆欣欣，王大海，郭兴青，林毅，张秋业<sup>*</sup></p><p>青岛大学附属医院儿科，山东 青岛</p><disp-formula id="hanspub.28595-formula11"><graphic xlink:href="//html.hanspub.org/file/14-1570800x5_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2019年1月2日；录用日期：2019年1月16日；发布日期：2019年1月23日</p><disp-formula id="hanspub.28595-formula12"><graphic xlink:href="//html.hanspub.org/file/14-1570800x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>目的：探讨儿童与成人系统性红斑狼疮(systemic lupus erythematosus, SLE)临床表现及实验室指标的差异。方法：收集2013年4月~2017年6月在青岛大学附属医院首诊为系统性红斑狼疮患者，根据起病年龄分为儿童组(≤14岁)和成人组(&gt;15岁)，分别进行组间临床表现、实验室指标、受累系统数量、SLEDAI (systemic lupus erythematosus disease activity index, SLEDAI)评分的比较。结果：共纳入108例SLE患者，成人组67例，儿童组41例。儿童组与成人组相比，颜面皮疹(68.3%/37.3%)、肌炎(14.6%/3.0%)、消化系统受累(36.6%/9.0%)、精神神经系统症状(29.2%/9.0%)、合并感染(65.9%/44.8%)的发生率差异有统计学差异(P &lt; 0.05)。儿童组受累器官更多(t = 2.27)，SLEDAI评分更高(t = 2.03)，成人组与儿童组相比，呼吸系统受累率(56.7%/14.1%)差异有统计学意义(P &lt; 0.05)。结论：成人与儿童SLE存在相似之处，但儿童SLE受累系统更多，临床表现更重。</p><p>关键词 :系统性红斑狼疮，儿童，成人，临床特点</p><disp-formula id="hanspub.28595-formula13"><graphic xlink:href="//html.hanspub.org/file/14-1570800x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2019 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/14-1570800x8_hanspub.png" /> <img src="//html.hanspub.org/file/14-1570800x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>系统性红斑狼疮(systemic lupus erythematosus, SLE)是一种病因未明的具有多种自身抗体的自身免疫性疾病。一般认为由遗传、环境、性激素等多种因素相互作用而引发自身免疫紊乱，可引起皮肤、肌肉、肾脏、中枢、血液等全身多个系统受累 [<xref ref-type="bibr" rid="hanspub.28595-ref1">1</xref>]。据国外资料报道，SLE患病率为14.6~122/10万人，而我国1985年的一次大样本调查显示患病率为70/10万人 [<xref ref-type="bibr" rid="hanspub.28595-ref2">2</xref>]。儿童期起病患者占总病例数15%~20%。儿童SLE起病常不典型，患病率较成人低，临床工作中常常忽视这一群体，易造成误诊、漏诊 [<xref ref-type="bibr" rid="hanspub.28595-ref1">1</xref>]。本研究旨在分析儿童与成人系统性红斑狼疮临床表现和实验室指标的差异，以提高对儿童系统性红斑狼疮的认识。</p></sec><sec id="s4"><title>2. 资料与方法</title><sec id="s4_1"><title>2.1. 研究对象</title><sec id="s4_1_1"><title>2.1.1. 病例入选标准</title><p>2013年4月~2017年6月在青岛大学附属医院住院并首次确诊为系统性红斑狼疮的病例。诊断标准采用1997年美国风湿病学会(American College of Rheumatology, ACR)修订的SLE诊断标准 [<xref ref-type="bibr" rid="hanspub.28595-ref3">3</xref>]。</p></sec><sec id="s4_1_2"><title>2.1.2. 排除标准</title><p>① 临床资料记录不完善者；② SLE合并其他结缔组织病、风湿热、皮肌炎、类风湿性关节炎、特发性血小板减少性紫癜等。</p></sec><sec id="s4_1_3"><title>2.1.3. 分组</title><p>根据确诊年龄分为儿童组(≤14岁)和成人组(&gt;15岁)。</p></sec></sec><sec id="s4_2"><title>2.2. 研究方法</title><sec id="s4_2_1"><title>2.2.1. 临床资料收集</title><p>包括发病年龄、性别、临床症状、受累系统(包括皮肤黏膜、关节肌肉、血液、呼吸、肾脏、心血管、消化、精神神经系统)、有无合并感染。</p></sec><sec id="s4_2_2"><title>2.2.2. 实验室指标收集</title><p>血常规、尿常规、肝肾功、血沉、补体、抗核抗体、ENA酶谱、24小时尿蛋白定量、胸片、心脏超声、颅脑MR等。</p></sec><sec id="s4_2_3"><title>2.2.3. SLE疾病活动度评估</title><p>采用1992年多伦多大学制定，2000年修订的SLEDAI评分系统 [<xref ref-type="bibr" rid="hanspub.28595-ref4">4</xref>] ，包括24个项目，共105分，根据受累器官及实验室指标将疾病活动程度分类如下：几乎不活动：0~4分；轻度活动：5~9分；中度活动：10~14分；重度活动：≥15分。</p></sec></sec><sec id="s4_3"><title>2.3. 统计方法</title><p>采用SPSS20.0版本软件进行统计分析，符合正态分布的计量资料以均数 &#177; 标准差( x &#175; &#177; s)表示，组间比较采用独立样本t检验；计数资料采用例(%)表示，组间比较采用χ<sup>2</sup>检验或采用Fisher精确概率检验。以P &lt; 0.05为差异具有统计学意义。</p></sec></sec><sec id="s5"><title>3. 结果</title><sec id="s5_1"><title>3.1. 一般情况</title><p>共纳入108例，儿童组41例，占38.0%，平均确诊年龄为9.4 &#177; 2.4，男女比例为1:4.8；成人组67例，占62.0%，平均确诊年龄为36.2 &#177; 12.7，男女比例为1:8.5。两组性别构成比差异无统计学意义(P &gt; 0.05)。</p></sec><sec id="s5_2"><title>3.2. 两组患者临床资料的比较</title><p>通过组间比较发现，SLE两组患者临床表现中儿童组颜面部皮疹、肌炎、血管炎、合并感染、消化系统及精神神经系统受累的比例明显高于成人组，而肺炎发生率低于成人组，差异具有统计学意义(P &lt; 0.05)，见表1。</p></sec><sec id="s5_3"><title>3.3. 两组患者实验室指标的比较</title><p>两组患者实验室指标的比较，包括抗核抗体、抗ds-DNA、抗Sm抗体、血沉、CRP、C<sub>3</sub>、C<sub>4</sub>、WBC、血小板减少、血红蛋白减少、蛋白尿、红细胞尿、管型尿、白细胞尿差异无统计学意义(P &gt; 0.05)，见表2。</p></sec><sec id="s5_4"><title>3.4. 两组患者受累系统及疾病活动程度的比较</title><p>通过比较发现，儿童组受累系统及发病初期疾病活动评分明显高于成人组，差异有统计学意义(P &lt; 0.05)，见表3。</p></sec></sec><sec id="s6"><title>4. 讨论</title><p>系统性红斑狼疮(SLE)是一种影响广泛的自身免疫性疾病，临床主要表现为颜面部皮疹、发热、乏力、口腔溃疡，可累及皮肤黏膜、骨骼肌肉、肾脏、消化道、血液及中枢神经等多个系统。SLE发病以青年女性多见，男女比例1:9，儿童仅占所有病例数的15%~20%，以青春期女童多见 [<xref ref-type="bibr" rid="hanspub.28595-ref5">5</xref>] ，因此常常被忽视。SLE发病存在种族差异，非洲裔美国人/非洲裔加勒比人和西班牙裔人发生这种疾病的可能性是欧洲–高加索人的三倍。目前认为SLE发病与环境、性激素、基因易感性相关 [<xref ref-type="bibr" rid="hanspub.28595-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.28595-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.28595-ref8">8</xref>] ，现已确定了数百个与SLE易感性有关的基因位点，通常编码免疫成分，包括HLA、IRF5、ITGAM、STAT4、BLK、CTLA4等，但是还有更多位点有待于发现。环境因素如药物、病毒感染(微小病毒、EB病毒)、紫外线、二氧化硅以及心理压力都有可能是SLE发病的易感因素 [<xref ref-type="bibr" rid="hanspub.28595-ref9">9</xref>] ，本研究统计了108位首诊的SLE患者，其中儿童占38.0%，平均年龄9.39 &#177; 2.36岁，其中9岁以上者占70.3%，研究发现儿童与成人SLE有诸多相似之处，常在以下方面存在一定差别。</p><p>颜面部皮疹是SLE常见临床表现，成人通常表现为蝶形红斑或环状红斑，但在儿童中临床表现常不典型，可仅表现为不规则红斑、陈旧性色素沉着、毛细血管扩张等，给临床医师的诊断带来一定困难 [<xref ref-type="bibr" rid="hanspub.28595-ref10">10</xref>]。本研究中儿童颜面皮疹的发病率也较高，约占68.3%，见表1，但本研究中儿童组颜面皮疹发病率高于成人组，这与国内一些报道不相符合 [<xref ref-type="bibr" rid="hanspub.28595-ref11">11</xref>] ，不除外本研究病例数偏少，存在误差可能。</p><p>消化系统受累在SLE中发生率较高，主要为SLE累及胃肠道引起的肠道血管炎，且临床表现无明显特异性，给该病带来极高的误诊率，甚至不少患儿被考虑为外科急腹症而进行手术。儿童SLE中约有20%可出现消化系统症状 [<xref ref-type="bibr" rid="hanspub.28595-ref12">12</xref>]。本研究中儿童组消化系统症状的发生率明显高于成人组，见表1，主要表现为脐周或无明确定位的下腹部疼痛，部分可仅为恶心、腹胀、食欲不振等不典型表现，经规范治疗后，绝大多数患儿的症状减轻或消失。狼疮性肠炎、肠系膜血管炎是SLE的少见并发症，可能与免疫复合物沉积和抗磷脂抗体相关的肠血管微血栓形成有关，临床表现从非特异性的腹胀、腹痛到严重的弥漫性腹痛、消化道出血甚至肠梗阻、肠穿孔均有可能，但其通常与SLE的其他临床表现并存，这提示临床医师在遇到反复腹痛的患儿除进行腹部查体及相关实验室检查外，还需注意有无其他腹部外的体征，必要时可进行抗磷脂抗体、抗ds-DNA抗体等相关实验室检查 [<xref ref-type="bibr" rid="hanspub.28595-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.28595-ref13">13</xref>]。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Comparison of clinical manifestations between children and adults with SL</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >临床表现</th><th align="center" valign="middle" >儿童组 [例数(%)]</th><th align="center" valign="middle" >成人组 [例数(%)]</th><th align="center" valign="middle" >X<sup>2</sup></th><th align="center" valign="middle" >P</th></tr></thead><tr><td align="center" valign="middle" >发热</td><td align="center" valign="middle" >22 (53.7)</td><td align="center" valign="middle" >33 (49.3)</td><td align="center" valign="middle" >0.197</td><td align="center" valign="middle" >0.657</td></tr><tr><td align="center" valign="middle" >颜面皮疹</td><td align="center" valign="middle" >28 (68.3)</td><td align="center" valign="middle" >25 (37.3)</td><td align="center" valign="middle" >9.768</td><td align="center" valign="middle" >0.002</td></tr><tr><td align="center" valign="middle" >光过敏</td><td align="center" valign="middle" >2 (4.9)</td><td align="center" valign="middle" >5 (7.5)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.462</td></tr><tr><td align="center" valign="middle" >口腔溃疡</td><td align="center" valign="middle" >4 (9.6)</td><td align="center" valign="middle" >9 (13.4)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.403</td></tr><tr><td align="center" valign="middle" >脱发</td><td align="center" valign="middle" >1 (2.4)</td><td align="center" valign="middle" >11 (16.4)</td><td align="center" valign="middle" >5.032</td><td align="center" valign="middle" >0.025</td></tr><tr><td align="center" valign="middle" >关节疼痛</td><td align="center" valign="middle" >12 (29.3)</td><td align="center" valign="middle" >28 (41.8)</td><td align="center" valign="middle" >1.71</td><td align="center" valign="middle" >0.191</td></tr><tr><td align="center" valign="middle" >血管炎</td><td align="center" valign="middle" >11 (26.8)</td><td align="center" valign="middle" >7 (10.4)</td><td align="center" valign="middle" >4.914</td><td align="center" valign="middle" >0.027</td></tr><tr><td align="center" valign="middle" >肌炎</td><td align="center" valign="middle" >6 (14.6)</td><td align="center" valign="middle" >2 (3.0)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.033</td></tr><tr><td align="center" valign="middle" >浆膜腔积液</td><td align="center" valign="middle" >14 (34.1)</td><td align="center" valign="middle" >30 (44.8)</td><td align="center" valign="middle" >1.190</td><td align="center" valign="middle" >0.275</td></tr><tr><td align="center" valign="middle" >肺部受累</td><td align="center" valign="middle" >14 (34.1)</td><td align="center" valign="middle" >38 (56.7)</td><td align="center" valign="middle" >5.190</td><td align="center" valign="middle" >0.023</td></tr><tr><td align="center" valign="middle" >心血管受累</td><td align="center" valign="middle" >8 (19.5)</td><td align="center" valign="middle" >7 (10.4)</td><td align="center" valign="middle" >1.747</td><td align="center" valign="middle" >0.186</td></tr><tr><td align="center" valign="middle" >肾脏损害</td><td align="center" valign="middle" >19 (46.3)</td><td align="center" valign="middle" >29 (43.3)</td><td align="center" valign="middle" >0.096</td><td align="center" valign="middle" >0.756</td></tr><tr><td align="center" valign="middle" >消化系统受累</td><td align="center" valign="middle" >15 (36.6)</td><td align="center" valign="middle" >6 (9.0)</td><td align="center" valign="middle" >12.397</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >精神神经系统受累</td><td align="center" valign="middle" >12 (29.2)</td><td align="center" valign="middle" >6 (9.0)</td><td align="center" valign="middle" >7.556</td><td align="center" valign="middle" >0.006</td></tr><tr><td align="center" valign="middle" >合并感染</td><td align="center" valign="middle" >27 (65.9)</td><td align="center" valign="middle" >30 (44.8)</td><td align="center" valign="middle" >4.534</td><td align="center" valign="middle" >0.033</td></tr></tbody></table></table-wrap><p>表1. 儿童组与成人SLE临床表现的比较</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Comparison of laboratory indicators between children and adults with SL</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >实验室指标</th><th align="center" valign="middle" >儿童组 [例数(%)]</th><th align="center" valign="middle" >成人组 [例数(%)]</th><th align="center" valign="middle" >X<sup>2</sup></th><th align="center" valign="middle" >P</th></tr></thead><tr><td align="center" valign="middle" >免疫学指标</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >抗核抗体</td><td align="center" valign="middle" >40 (97.6)</td><td align="center" valign="middle" >66 (98.5)</td><td align="center" valign="middle" >0.125</td><td align="center" valign="middle" >0.723</td></tr><tr><td align="center" valign="middle" >抗ds-DNA抗体</td><td align="center" valign="middle" >19 (46.3)</td><td align="center" valign="middle" >29 (43.3)</td><td align="center" valign="middle" >0.096</td><td align="center" valign="middle" >0.756</td></tr><tr><td align="center" valign="middle" >抗Sm抗体</td><td align="center" valign="middle" >11 (26.8)</td><td align="center" valign="middle" >15 (22.4)</td><td align="center" valign="middle" >0.274</td><td align="center" valign="middle" >0.600</td></tr><tr><td align="center" valign="middle" >血沉增快</td><td align="center" valign="middle" >31 (75.6)</td><td align="center" valign="middle" >41 (61.2)</td><td align="center" valign="middle" >2.379</td><td align="center" valign="middle" >0.123</td></tr><tr><td align="center" valign="middle" >CRP升高</td><td align="center" valign="middle" >6 (14.6)</td><td align="center" valign="middle" >20 (29.9)</td><td align="center" valign="middle" >3.222</td><td align="center" valign="middle" >0.073</td></tr><tr><td align="center" valign="middle" >C<sub>3</sub>下降</td><td align="center" valign="middle" >34 (82.9)</td><td align="center" valign="middle" >51 (76.1)</td><td align="center" valign="middle" >0.703</td><td align="center" valign="middle" >0.402</td></tr><tr><td align="center" valign="middle" >C<sub>4</sub>下降 血液学指标</td><td align="center" valign="middle" >29 (70.7)</td><td align="center" valign="middle" >39 (58.2)</td><td align="center" valign="middle" >1.710</td><td align="center" valign="middle" >0.191</td></tr><tr><td align="center" valign="middle" >白细胞减少</td><td align="center" valign="middle" >11 (26.8)</td><td align="center" valign="middle" >17 (25.4)</td><td align="center" valign="middle" >0.028</td><td align="center" valign="middle" >0.867</td></tr><tr><td align="center" valign="middle" >血小板降低</td><td align="center" valign="middle" >13 (31.7)</td><td align="center" valign="middle" >22 (32.8)</td><td align="center" valign="middle" >0.015</td><td align="center" valign="middle" >0.903</td></tr><tr><td align="center" valign="middle" >血红蛋白降低</td><td align="center" valign="middle" >16 (39.0)</td><td align="center" valign="middle" >33 (49.3)</td><td align="center" valign="middle" >1.074</td><td align="center" valign="middle" >0.300</td></tr><tr><td align="center" valign="middle" >尿液分析指标</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >蛋白尿</td><td align="center" valign="middle" >16 (39.0)</td><td align="center" valign="middle" >30 (44.8)</td><td align="center" valign="middle" >0.344</td><td align="center" valign="middle" >0.557</td></tr><tr><td align="center" valign="middle" >红细胞尿</td><td align="center" valign="middle" >20 (48.8)</td><td align="center" valign="middle" >24 (35.8)</td><td align="center" valign="middle" >1.769</td><td align="center" valign="middle" >0.183</td></tr><tr><td align="center" valign="middle" >管型尿</td><td align="center" valign="middle" >3 (7.3)</td><td align="center" valign="middle" >2 (3.0)</td><td align="center" valign="middle" >1.081</td><td align="center" valign="middle" >0.298</td></tr><tr><td align="center" valign="middle" >白细胞尿</td><td align="center" valign="middle" >17 (41.5)</td><td align="center" valign="middle" >21 (31.3)</td><td align="center" valign="middle" >1.142</td><td align="center" valign="middle" >0.285</td></tr></tbody></table></table-wrap><p>表2. 儿童组与成人组SLE实验室指标的比较</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Comparison of involved systems and SLEDAI scores between children and adults with SLE ( x &#175; &#177; s</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >儿童组</th><th align="center" valign="middle" >成人组</th><th align="center" valign="middle" >t</th><th align="center" valign="middle" >P</th></tr></thead><tr><td align="center" valign="middle" >受累系统</td><td align="center" valign="middle" >3.49 &#177; 1.66</td><td align="center" valign="middle" >2.81 &#177; 1.23</td><td align="center" valign="middle" >2.27</td><td align="center" valign="middle" >0.026</td></tr><tr><td align="center" valign="middle" >SLEDAI积分</td><td align="center" valign="middle" >13.98 &#177; 9.48</td><td align="center" valign="middle" >10.69 &#177; 5.42</td><td align="center" valign="middle" >2.03</td><td align="center" valign="middle" >0.047</td></tr></tbody></table></table-wrap><p>表3. 儿童组与成人组SLE受累系统和SLEDAI积分的比较( x &#175; &#177; s)</p><p>精神神经狼疮(Neuropsychiatric systemic lupus erythematosus, NPSLE)是SLE病情严重的重要表现，约有25%的儿童中有精神神经症状，并可发生于病程的任何阶段，最常见发生于起病1年内，约占70% [<xref ref-type="bibr" rid="hanspub.28595-ref14">14</xref>] ，且是一种独立危险因素 [<xref ref-type="bibr" rid="hanspub.28595-ref15">15</xref>]。神经精神症状的存在是SLE重要危险因素，可加重SLE的累积损害 [<xref ref-type="bibr" rid="hanspub.28595-ref15">15</xref>]。NPSLE发病机制复杂，与血管炎、血栓形成及多种自身抗体有关 [<xref ref-type="bibr" rid="hanspub.28595-ref14">14</xref>] ，目前尚未有明确的特异性指标可以提示该病，这给临床工作带来一定困难。近年来报道抗核糖体P蛋白及抗磷脂抗体阳性与患NPSLE的发生有关，考虑到NPSLE是一种具有多样临床表现的复杂的自身免疫性疾病，单一的自身抗体难以解释所有不同的精神神经症状 [<xref ref-type="bibr" rid="hanspub.28595-ref16">16</xref>]。血清神经元特异性烯醇化酶(neuron specific enolase, NSE)是一种糖酵解酶，可以反应神经元的代谢活性，有研究指出NPSLE的活动度与血清中NSE的水平呈负相关，反应了NPSLE发病过程中神经系统的的慢性病理损伤，但因该研究样本量小使得该研究的价值有限 [<xref ref-type="bibr" rid="hanspub.28595-ref17">17</xref>]。本研究中SLE儿童组神经系统受累的发生率为29.2%，明显高于成人组，见表1，国外报道在儿童NPSLE中有高达55%的患儿可出现认知功能障碍，包括单词识别、记忆和注意力障碍，这提示我们在青少年SLE中，患儿出现学习成绩大幅度下降可能提示存在NPSLE的可能，需要及时进行病情活动度评估 [<xref ref-type="bibr" rid="hanspub.28595-ref14">14</xref>]。</p><p>本研究中儿童组血管炎的发生率高于成人组，见表1，除了皮肤受累外，SLE血管炎可影响全身各个脏器，包括消化道、视网膜，甚至肾脏、颅脑等重要脏器 [<xref ref-type="bibr" rid="hanspub.28595-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.28595-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.28595-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.28595-ref19">19</xref>]。当累及重要器官时，SLEDAI评分明显升高，对患儿机体的累积损害增加，死亡率也会随之升高。国外研究报道低补体血症、狼疮性肾炎、骨骼肌肉受累等可能是血管炎发生的危险因素 [<xref ref-type="bibr" rid="hanspub.28595-ref20">20</xref>]。</p><p>肾脏是SLE受累的主要靶器官，40%~70%的SLE儿童可发展为狼疮性肾炎(Lupus nephritis, LN)，临床表现从无症状的血尿、蛋白尿到急性肾衰竭都有可能发生，肾脏活检是了解狼疮肾炎病理变化的重要手段。本研究中儿童组肾脏损害发生率为46.3%，仅次于皮疹(68.3%)、合并感染(65.9%)、发热(53.7%)，见表1，主要表现为血尿、蛋白尿，肾功能衰竭者少见，共有11名儿童接受肾脏活检，病理分级Ⅳ级及以上者为5例(45.5%)，Ⅳ型LN是SLE最常见的组织病理学表现，本研究与文献报道大致相同 [<xref ref-type="bibr" rid="hanspub.28595-ref21">21</xref>]。</p><p>多种自身抗体的产生是SLE的特点之一，它们可以形成免疫复合物沉积在不同的靶器官，造成全身多系统损害。在出现临床症状之前自身抗体便已经有了变化。在SLE中敏感性最强的自身抗体便是抗核抗体(&gt;98%)，但其特异性较低，在其他结缔组织病中也可出现抗核抗体阳性，甚至在健康人群中有20%~33%的阳性率，因此当患儿出现抗核抗体阳性时我们仍需参考其他实验室检查及临床表现 [<xref ref-type="bibr" rid="hanspub.28595-ref22">22</xref>]。但是因其高敏感性，可作为筛查SLE的手段，尤其是高滴度的抗核抗体，对SLE的诊断具有很大的参考价值。另外，SLE发病初期抗核抗体可为阴性或者弱阳性，临床医师需对高危患儿定期随访，避免漏诊。相比之下，抗ds-DNA抗体、抗sm抗体和抗核蛋白抗体在正常人中非常罕见。本研究中儿童抗核抗体的阳性率为97.6%，成人抗核抗体的阳性率为98.5%，两组数据无统计学差异，提示儿童与成人SLE在实验室检查上存在共同之处。</p><p>新生儿狼疮(Neonatal Lupus Erythematosus, NLE)和药物性狼疮是SLE的特殊类型。新生儿狼疮是一种罕见的疾病，与母体自身抗体经胎盘途径进入胎儿循环和新生儿自身有关。环境因素和遗传因素可能参与NLE的发病或者发挥增强抗体的作用。约95%的母亲存在抗体SSA/Ro、SSB/La阳性，但是只有一半的母亲是风湿性疾病患者，如SLE、类风湿性关节炎、结缔组织病等，另外50%母亲仅表现为血清学抗体的阳性，并无SLE相关临床症状。NLE患儿最常见临床表现为皮肤红斑狼疮和先天性心脏传导阻滞，皮疹主要发生于颜面部，表现为多发性红斑、环状红斑，10%~35%的患儿可有血液学表现，主要为血小板减少症、中性粒细胞减少症和贫血 [<xref ref-type="bibr" rid="hanspub.28595-ref23">23</xref>]。部分患儿可有肝胆疾病或者中枢神经系统受累，肝脏受累即可表现为轻微的肝功能异常，也可表现为肝功能衰竭。中枢神经系统受累的发生率仅为1.4%。NLE的治疗主要以激素治疗为主，对于有三度房室传导阻滞的患儿需要安装起搏器。本研究中未收集到新生儿狼疮的的相关病例，但是作为SLE的特殊类型，需要引起临床医师的注意。</p><p>药物性狼疮(Drug-induced Lupus erythematosus, DILE)是一种狼疮样自身免疫性疾病，通常发生在长期接触某种药物之后，目前已有100多种药物与药物性狼疮有关，其中化疗药物是亚急性DILE最常见的药物类别，近些年随着新型药物(新型抗肿瘤药物及生物调节剂)的应用，引发DILE的药物清单也逐渐扩大 [<xref ref-type="bibr" rid="hanspub.28595-ref24">24</xref>]。目前认为DILE的发病机制主要包括遗传易感性、药物生物转化和不同免疫细胞的表观遗传失调。DILE主要分为三种临床类型：全身型、亚急性型、慢性皮肤型，它的临床表现差异很大，主要以全身症状为主(低热、厌食、体重减轻、疲劳)，有时以关节炎、浆膜炎为特征，很少有中枢神经系统、肾脏、胃肠道和血液系统受累，典型的皮疹也很少见。总体而言，DILE的临床表现较SLE要轻很多，停用引发DILE的药物数周到数月并针对临床表现采取针对性处理措施，大多数DILE可治愈。但当出现主要器官受累(如肾小球肾炎、中枢神经系统受累、严重的血液学异常)时，必须结合全身免疫抑制疗法和治疗方案 [<xref ref-type="bibr" rid="hanspub.28595-ref25">25</xref>]。本研究中尚未发现药物性狼疮的病例。</p><p>另外，本研究中儿童组感染发生率、受累系统及SLEDAI评分明显高于成人组，这与大多数文献报道相符 [<xref ref-type="bibr" rid="hanspub.28595-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.28595-ref26">26</xref>] [<xref ref-type="bibr" rid="hanspub.28595-ref27">27</xref>] ，而成人肺部受累率则明显高于儿童(56.7%/34.1%)，见表1。文献报道成人50岁前后诊断SLE的十年生存率为97.8%和89.5% [<xref ref-type="bibr" rid="hanspub.28595-ref28">28</xref>] ，儿童SLE十年生存率约80%~90% [<xref ref-type="bibr" rid="hanspub.28595-ref29">29</xref>] [<xref ref-type="bibr" rid="hanspub.28595-ref30">30</xref>] ，相比于成人仍较低，但儿童SLE及时有效的干预对其生存期的延长有重要意义。</p><p>儿童SLE的治疗目前没有相关指南基本参考成人治疗方案，2017年欧洲基于儿童SLE诊疗建议指出，所有儿童SLE均应常规服用羟氯喹，以减少狼疮复发及延长生存期。该文章同时指出，儿童服药非依从性可高达50%，当改变治疗方案或治疗反应不佳时应及时评估患儿药物的依从性 [<xref ref-type="bibr" rid="hanspub.28595-ref31">31</xref>]。近年来生物制剂被越来越多的应用于临床，利妥昔单抗是抗CD20的单克隆抗体，可以抑制B淋巴细胞的成熟和分化，在难治性SLE和狼疮性肾炎中具有较高的有效率，值得注意的是任何生物制剂应用6个月需及时重新评估患者疾病活动 [<xref ref-type="bibr" rid="hanspub.28595-ref32">32</xref>]。</p><p>综上，儿童SLE与成人SLE有许多相似之处，但儿童SLE更易出现消化、神经系统症状，合并感染，皮疹及血管炎、肌炎的发生率也较成人高；实验室检查方面与成人大致相同，ACR成人诊断标准同样适合儿童。但是儿童SLE的SLEDAI评分较成人明显升高，受累器官多于成人，提示儿童SLE的疾病活动度更高，病情更凶险，需要引起儿科医师的重视。</p></sec><sec id="s7"><title>声明</title><p>本研究无相关利益冲突关系，符合医学伦理委员会要求，已获得青岛大学附属医院医学伦理委员会审批。</p></sec><sec id="s8"><title>文章引用</title><p>荆欣欣,王大海,郭兴青,林 毅,张秋业. 儿童与成人系统性红斑狼疮的临床特点分析Clinical Characteristics of Systemic Lupus Erythematosus in Children and Adults[J]. 临床医学进展, 2019, 09(01): 80-87. https://doi.org/10.12677/ACM.2019.91014</p></sec><sec id="s9"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.28595-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">中华医学会儿科学分会免疫学组,《中华儿科杂志》编辑委员会. 儿童系统性红斑狼疮诊疗建议[J]. 中华儿科杂志, 2011, 49(7): 506-514.</mixed-citation></ref><ref id="hanspub.28595-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">中华医学会风湿病学分会. 系统性红斑狼疮诊治指南(草案) [J]. 中华风湿病学杂志, 2003, 7(8): 508-513.</mixed-citation></ref><ref id="hanspub.28595-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Hochberg, M.C. (1997) Updating the American College of Rheumatology Revised Cri-teria for the Classification of Systemic Lupus Erythematosus. Arthritis and Rheumatism, 40, 1725. &lt;br&gt;https://doi.org/10.1002/art.1780400928</mixed-citation></ref><ref id="hanspub.28595-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Cook, R.J., Gladman, D.D., Pericak, D., et al. (2000) Prediction of Short Term Mortality in Systemic Lupus Erythematosus with Time Dependent Measures of Disease Activity. The Journal of Rheumatology, 27, 1892-1895.</mixed-citation></ref><ref id="hanspub.28595-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Groot, N., Shaikhani, D., Teng, Y.K.O., et al. (2018) Long-Term Clin-ical Outcomes in a Cohort of Adults with Childhood-Onset Systemic Lupus Erythematosus. Arthritis &amp; Rheumatology. &lt;br&gt;https://doi.org/10.1002/art.40697</mixed-citation></ref><ref id="hanspub.28595-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Mousa, T.G., Omar, H.H., Emad, R., et al. (2018) The Association of CD40 Polymorphism (rs1883832C/T) and Soluble CD40 with the Risk of Systemic Lupus Erythematosus among Egyptian Patients. Clinical Rheumatology.  
&lt;br&gt;https://doi.org/10.1007/s10067-018-4349-y</mixed-citation></ref><ref id="hanspub.28595-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Ciccacci, C., Perricone, C., Ceccarelli, F., et al. (2014) A Multi-locus Genetic Study in a Cohort of Italian SLE Patients Confirms the Association with STAT4 Gene and Describes a New Association with HCP5 Gene. PLoS One, 9, e111991. &lt;br&gt;https://doi.org/10.1371/journal.pone.0111991</mixed-citation></ref><ref id="hanspub.28595-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Marks, S.D. and Tullus, K. (2012) Autoantibodies in Systemic Lupus Erythematosus. Pediatric Nephrology, 27, 1855-1868. &lt;br&gt;https://doi.org/10.1007/s00467-011-2078-4</mixed-citation></ref><ref id="hanspub.28595-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Mireles-Canales, M.P., Gonzalez-Chavez, S.A., Quinonez-Flores, C.M., et al. (2018) DNA Damage and Deficiencies in the Mechanisms of Its Repair: Implications in the Pathogenesis of Systemic Lupus Erythematosus. Journal of Immunology Research, 2018, 8214379. &lt;br&gt;https://doi.org/10.1155/2018/8214379</mixed-citation></ref><ref id="hanspub.28595-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">潘延斌, 李建民, 刘京平, 林有坤. 首诊儿童与成人系统性红斑狼疮病例的临床比较分析[J]. 广西医科大学学报, 2011, 28(5): 729-731.</mixed-citation></ref><ref id="hanspub.28595-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">尧雨根. 儿童与成人系统性红斑狼疮的临床特点比较[J]. 海南医学, 2012, 23(22): 84-85.</mixed-citation></ref><ref id="hanspub.28595-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Chowichian, M., Aanpreung, P., Pongpaibul, A., et al. (2018) Lupus Enteritis as the Sole Presenting Feature of Systemic Lupus Erythematosus: Case Report and Review of the Literature. Paediatrics and International Child Health, 1-5. &lt;br&gt;https://doi.org/10.1080/20469047.2018.1504430</mixed-citation></ref><ref id="hanspub.28595-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Liu, Y., Zhu, J., Lai, J.M., et al. (2018) Reports of Three Cases with the Initial Presentation of Mesenteric Vasculitis in Children with System Lupus Erythematous. Clinical Rheumatology, 37, 277-283.  
&lt;br&gt;https://doi.org/10.1007/s10067-017-3841-0</mixed-citation></ref><ref id="hanspub.28595-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Soybilgic, A. (2015) Neuropsychiatric Systemic Lupus Erythe-matosus in Children. Pediatric Annals, 44, e153-e158.  
&lt;br&gt;https://doi.org/10.3928/00904481-20150611-11</mixed-citation></ref><ref id="hanspub.28595-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Sit, J.K.K. and Chan, W.K.Y. (2018) Risk Factors for Damage in Childhood-Onset Systemic Lupus Erythematosus in Asians: A Case Control Study. Pediatric Rheumatology, 16.</mixed-citation></ref><ref id="hanspub.28595-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Kalinowska-Lyszczarz, A., Pawlak, M.A., Wyciszkiewicz, A., et al. (2017) Immune Cell Neurotrophin Production Is Associated with Subcortical Brain Atrophy in Neuropsychiatric Systemic Lupus Erythematosus Patients. Neuroimmunomodulation, 24, 320-330. &lt;br&gt;https://doi.org/10.1159/000487139</mixed-citation></ref><ref id="hanspub.28595-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Hawro, T., Bogucki, A., Krupinska-Kun, M., et al. (2015) Serum Neuron Specific Enolase—A Novel Indicator for Neuropsychiatric Systemic Lupus Erythematosus? Lupus, 24, 1492-1497. &lt;br&gt;https://doi.org/10.1177/0961203315593818</mixed-citation></ref><ref id="hanspub.28595-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Monov, S., Hris-tova, R., Dacheva, R., et al. (2017) Acute Necrotizing Retinal Vasculitis as Onset of Systemic Lupus Erythematosus: A Case Report. Medicine (Baltimore), 96, e5754. &lt;br&gt;https://doi.org/10.1097/MD.0000000000005754</mixed-citation></ref><ref id="hanspub.28595-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Kaul, A., Agrawal, V., Bhaduaria, D., et al. (2017) Vasculitis and Vasculopathy in Lupus Nephritis: Clinical Variability, Outcome, and New Insight into Treatment. Saudi Journal of Kidney Disease and Transplantation, 28, 415-424.  
&lt;br&gt;https://doi.org/10.4103/1319-2442.202777</mixed-citation></ref><ref id="hanspub.28595-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Gheita, T.A., Abaza, N.M., Sayed, S., et al. (2017) Cutaneous Vasculitis in Systemic Lupus Erythematosus Patients: Potential Key Players and Implications. Lupus.</mixed-citation></ref><ref id="hanspub.28595-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Lee, P.Y., Yeh, K.W., Yao, T.C., et al. (2013) The Outcome of Patients with Renal Involvement in Pediatric-Onset Systemic Lupus Erythematosus—A 20-Year Experience in Asia. Lupus, 22, 1534-1540.  
&lt;br&gt;https://doi.org/10.1177/0961203313502110</mixed-citation></ref><ref id="hanspub.28595-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Mok, C.C. (2018) Systemic Lupus Erythematosus: What Should Family Physicians Know in 2018? Hong Kong Medical Journal, 24, 501-511. &lt;br&gt;https://doi.org/10.12809/hkmj187319</mixed-citation></ref><ref id="hanspub.28595-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Teixeira, A.R., Rodrigues, M., Guimaraes, H., et al. (2017) Neonatal Lupus—Case Series of a Tertiary Hospital. Acta Reumatológica Portuguesa, 42, 318-323.</mixed-citation></ref><ref id="hanspub.28595-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">He, Y. and Sawalha, A.H. (2018) Drug-Induced Lupus Erythematosus: An Update on Drugs and Mechanisms. Current Opinion in Rheuma-tology, 30, 490-497. &lt;br&gt;https://doi.org/10.1097/BOR.0000000000000522</mixed-citation></ref><ref id="hanspub.28595-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Vaglio, A., Grayson, P.C., Fenaroli, P., et al. (2018) Drug-Induced Lupus: Traditional and New Concepts. Autoimmunity Reviews, 17, 912-918. &lt;br&gt;https://doi.org/10.1016/j.autrev.2018.03.016</mixed-citation></ref><ref id="hanspub.28595-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">秦凤, 于清, 曹兰芳, 卢燕鸣. 儿童系统性红斑狼疮合并感染86例的临床分析[J]. 现代生物医学进展, 2017, 17(2): 260-264.</mixed-citation></ref><ref id="hanspub.28595-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">文振华, 左晓霞, 周亚欧. 儿童与成人系统性红斑狼疮的临床和免疫学特征比较[J]. 临床误诊误治, 2012, 25(10): 64-66.</mixed-citation></ref><ref id="hanspub.28595-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Merola, J.F., Bermas, B., Lu, B., et al. (2014) Clinical Manifestations and Survival among Adults with (SLE) According to Age at Diagnosis. Lupus, 23, 778-784. &lt;br&gt;https://doi.org/10.1177/0961203314526291</mixed-citation></ref><ref id="hanspub.28595-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Huang, J.L., Yeh, K.W., Yao, T.C., et al. (2010) Pediatric Lupus in Asia. Lupus, 19, 1414-1418.  
&lt;br&gt;https://doi.org/10.1177/0961203310374339</mixed-citation></ref><ref id="hanspub.28595-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Brunner, H.I., Huggins, J. and Klein-Gitelman, M.S. (2011) Pe-diatric SLE—Towards a Comprehensive Management Plan. Nature Reviews Rheumatology, 7, 225-233. &lt;br&gt;https://doi.org/10.1038/nrrheum.2011.15</mixed-citation></ref><ref id="hanspub.28595-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Groot, N., de Graeff, N., Avcin, T., et al. (2017) European Evi-dence-Based Recommendations for Diagnosis and Treatment of Childhood-Onset Systemic Lupus Erythematosus: The SHARE Initiative. Annals of the Rheumatic Diseases, 76, 1788-1796. &lt;br&gt;https://doi.org/10.1136/annrheumdis-2016-210960</mixed-citation></ref><ref id="hanspub.28595-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Kleinmann, J.F., Tubach, F., Le Guern, V., et al. (2017) International and Multidisciplinary Expert Recommendations for the Use of Biologics in Systemic Lupus Erythematosus. Autoimmunity Reviews, 16, 650-657.  
&lt;br&gt;https://doi.org/10.1016/j.autrev.2017.04.011</mixed-citation></ref></ref-list></back></article>